Moleculin Biotech, Inc. (MBRX)

Intra-Cellular Therapies Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-23.23	-21.76	-29.77	-29.03	-15.89	-17.36
Depreciation & Amortization	0.13	0.13	0.13	0.13	0.16	0.2
Loss (Gain) From Sale of Assets	-	-	-	-	-	0.01
Stock-Based Compensation	1.72	1.73	1.98	2.28	2.37	1.68
Other Operating Activities	-2.19	-4.18	2.45	-1.24	-6.63	-2.26
Change in Accounts Payable	0.6	-0.47	0.4	0.73	0.24	-1.02
Change in Other Net Operating Assets	1.26	0.7	1.22	-0.51	0.8	0.98
Operating Cash Flow	-21.71	-23.86	-23.59	-27.64	-18.95	-17.77
Capital Expenditures	-0.01	-0.01	-0.12	-0.07	-0.02	-0.38
Sale of Property, Plant & Equipment	-	-	-	-	-	0
Investing Cash Flow	-0.01	-0.01	-0.12	-0.07	-0.02	-0.37
Issuance of Common Stock	12.66	4.66	4.17	-	74.75	22.57
Repurchase of Common Stock	-0.03	-0.03	-0.03	-0.02	-0.02	-0.02
Financing Cash Flow	12.63	4.64	4.14	-0.02	74.72	22.55
Foreign Exchange Rate Adjustments	-0.02	-0.03	-0.02	-0.03	-0.02	0.03
Net Cash Flow	-9.11	-19.27	-19.6	-27.76	55.73	4.44
Free Cash Flow	-21.72	-23.88	-23.72	-27.71	-18.97	-18.15
Free Cash Flow Per Share	-4.21	-6.93	-12.00	-14.53	-10.59	-27.65
Cash Income Tax Paid	-	-	-	-	-	0.02
Levered Free Cash Flow	-12.26	-14.36	-14.6	-16.09	-10.17	-10.77
Unlevered Free Cash Flow	-12.26	-14.36	-14.6	-16.09	-10.17	-10.77
Change in Net Working Capital	-1.98	-0.33	-1.74	-0.32	-1.16	-0.06

Updated Mar 21, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q